717 related articles for article (PubMed ID: 32053298)
21. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
Furuta S; Sugiyama T; Umibe T; Kaneko Y; Amano K; Kurasawa K; Nakagomi D; Hiraguri M; Hanaoka H; Sato Y; Ikeda K; Nakajima H;
BMJ Open; 2017 Dec; 7(12):e018748. PubMed ID: 29247107
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review.
Xiao Y; Guyatt G; Zeng L; Rw Jayne D; A Merkel P; Ac Siemieniuk R; Dookie JE; A Buchan T; Ahmed MM; J Couban R; Mahr A; Walsh M
BMJ Open; 2022 Feb; 12(2):e050507. PubMed ID: 35217533
[TBL] [Abstract][Full Text] [Related]
23. Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis".
Soulsby WD
ACR Open Rheumatol; 2022 Jul; 4(7):558-561. PubMed ID: 35167187
[TBL] [Abstract][Full Text] [Related]
24. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
Ann Rheum Dis; 2024 Jan; 83(1):96-102. PubMed ID: 37734880
[TBL] [Abstract][Full Text] [Related]
25. Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Gopaluni S; Flossmann O; Little MA; O'Hara P; Bekker P; Jayne D;
Arthritis Rheumatol; 2019 May; 71(5):784-791. PubMed ID: 30418705
[TBL] [Abstract][Full Text] [Related]
26. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality.
Wallace ZS; Fu X; Cook C; Ahola C; Williams Z; Doliner B; Hanberg JS; Stone JH; Zhang Y; Choi HK
Arthritis Rheumatol; 2023 Sep; 75(9):1599-1607. PubMed ID: 37011036
[TBL] [Abstract][Full Text] [Related]
28. Plasma exchange in ANCA-associated vasculitis: the pro position.
Kronbichler A; Shin JI; Wang CS; Szpirt WM; Segelmark M; Tesar V
Nephrol Dial Transplant; 2021 Jan; 36(2):227-231. PubMed ID: 33374018
[TBL] [Abstract][Full Text] [Related]
29. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease.
McGregor JG; Hogan SL; Hu Y; Jennette CE; Falk RJ; Nachman PH
Clin J Am Soc Nephrol; 2012 Feb; 7(2):240-7. PubMed ID: 22134625
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P; Bruchfeld A; Cid MC; Dahlsveen K; de Zoysa J; Espigol-Frigolé G; Lanyon P; Peh CA; Tesar V; Vaglio A; Walsh M; Walsh D; Walters G; Harper L; Jayne D;
Ann Rheum Dis; 2019 Mar; 78(3):399-405. PubMed ID: 30612116
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.
McAdoo SP; Medjeral-Thomas N; Gopaluni S; Tanna A; Mansfield N; Galliford J; Griffith M; Levy J; Cairns TD; Jayne D; Salama AD; Pusey CD
Nephrol Dial Transplant; 2019 Jan; 34(1):63-73. PubMed ID: 29462348
[TBL] [Abstract][Full Text] [Related]
32. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Pulmonary Vasculitis.
Terrier B; Guillevin L
Semin Respir Crit Care Med; 2018 Aug; 39(4):504-510. PubMed ID: 30404117
[TBL] [Abstract][Full Text] [Related]
34. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
35. The Effects of Plasma Exchange on Severe Vasculitis with Diffuse Alveolar Hemorrhage.
Goto K; Nakai K; Fujii H; Nishi S
Intern Med; 2017; 56(1):55-59. PubMed ID: 28050000
[TBL] [Abstract][Full Text] [Related]
36. Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group.
de Luna G; Chauveau D; Aniort J; Carron PL; Gobert P; Karras A; Marchand-Adam S; Maurier F; Hatron PY; Mania A; le Guenno G; Bally S; Bienvenu B; Cardineau E; Goulenok T; Jourde-Chiche N; Samson M; Huart A; Pourrat J; Tiple A; Aumaitre O; Puéchal X; Heshmati F; le Jeunne C; Mouthon L; Guillevin L; Terrier B;
J Autoimmun; 2015 Dec; 65():49-55. PubMed ID: 26330347
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
38. ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.
Andreiana I; Stancu S; Avram A; Taran L; Mircescu G
BMC Nephrol; 2015 Jun; 16():90. PubMed ID: 26123651
[TBL] [Abstract][Full Text] [Related]
39. Plasma exchange as an adjunctive therapy in anti-neutrophil cytoplasm antibody-associated vasculitis.
Gulati K; Pusey CD
Expert Rev Clin Immunol; 2023 Apr; 19(4):417-430. PubMed ID: 36860127
[TBL] [Abstract][Full Text] [Related]
40. Treatment Strategies in ANCA-Associated Vasculitis.
Emejuaiwe N
Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
